Neurobiology of Aging
Volume 31, Issue 10 , Pages 1732-1742 , October 2010

Th1 responses to beta-amyloid in young humans convert to regulatory IL-10 responses in Down syndrome and Alzheimer's disease

  • Kai F. Loewenbrueck

      Affiliations

    • Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    • Division of Endocrinology, Department of Medicine, University Hospital Ulm, 89081 Ulm, Germany
    • Department of Neurology, University Hospital “Carl Gustav Carus”, Dresden University of Technology, 01307 Dresden, Germany
    • Corresponding Author InformationCorresponding author at: Department of Pathology, Wolstein Research Building, Room # 5128, Case Western Reserve University, 10900 Euclid Ave., Cleveland, OH 44106, USA. Permanent address: Department of Neurology, University Hospital “Carl Gustav Carus”, Dresden University of Technology, 01307 Dresden, Germany. Tel.: +49 351 458 2532.
    • ,
  • Justine T. Tigno-Aranjuez

      Affiliations

    • Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    • Tel.: +1 216 368 1365; fax: +1 216 368 1357.
    • ,
  • Bernhard O. Boehm

      Affiliations

    • Division of Endocrinology, Department of Medicine, University Hospital Ulm, 89081 Ulm, Germany
    • Tel.: +49 731 500 44504; fax: +49 731 500 44506.
    • ,
  • Paul V. Lehmann

      Affiliations

    • Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    • Tel.: +1 216 368 1365; fax: +1 216 368 1357.
    • ,
  • Magdalena Tary-Lehmann

      Affiliations

    • Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA
    • Tel.: +1 216 368 1298; fax: +1 216 368 1357.

Received 9 November 2007 ,Revised 22 August 2008 ,Accepted 16 September 2008.

References 

  1. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol. 2001;2:675–680(Review) (84 refs.)
  2. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000;6:916–919
  3. Berard M, Tough DF. Qualitative differences between naive and memory T cells. Immunology. 2002;106:127–138
  4. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W, et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J. Clin. Invest. 2004;114:427–437
  5. Blasko I, Grubeck-Loebenstein B. Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging. 2003;20:101–113(Review) (86 refs.)
  6. Brettschneider S, Morgenthaler NG, Teipel SJ, Fischer-Schulz C, Burger K, Dodel R, et al. Decreased serum amyloid beta(1–42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1–42) peptide. Biol. Psychiatry. 2005;57:813–816
  7. Campbell A. Beta-amyloid: friend or foe. Med. Hypotheses. 2001;56:388–391
  8. Ciaramella, A., Sanarico, N., Bizzoni, F., Moro, M.L., Salani, F., Scapigliati, G., Spalletta, G., Caltagirone, C., Bossu, P., 2007. Amyloid beta peptide promotes differentiation of pro-inflammatory human myeloid dendritic cells. Neurobiol. Aging, Epub ahead of print, PMID: 17658667 (PubMed – as supplied by publisher).
  9. Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. Reduced effectiveness of Abeta1–42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol. Aging. 2001;22:721–727
  10. DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science. 2002;295:2264–2267
  11. Deng Y, Jing Y, Campbell AE, Gravenstein S. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 2004;172:3437–3446
  12. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801–805
  13. Ferrer I, Boada RM, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 2004;14:11–20
  14. Finch CE, Marchalonis JJ. Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease. Neurobiol. Aging. 1996;17:809–815(Review) (131 refs.)
  15. Guerkov RE, Targoni OS, Kreher CR, Boehm BO, Herrera MT, Tary-Lehmann M, et al. Detection of low-frequency antigen-specific IL-10-producing CD4(+) T cells via ELISPOT in PBMC: cognate vs. nonspecific production of the cytokine. J. Immunol. Methods. 2003;279:111–121
  16. Haynes L, Swain SL. Why aging T cells fail: implications for vaccination. Immunity. 2006;24:663–666
  17. Helms T, Boehm BO, Asaad RJ, Trezza RP, Lehmann PV, Tary-Lehmann M. Direct visualization of cytokine-producing recall antigen-specific CD4 memory T cells in healthy individuals and HIV patients. J. Immunol. 2000;164:3723–3732
  18. Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J. Leukocyte Biol. 2003;74:471–478(Review) (87 refs.)
  19. Isacson O, Seo H, Lin L, Albeck D, Granholm AC. Alzheimer's disease and Down's syndrome: roles of APP, trophic factors and ACh. Trends Neurosci. 2002;25:79–84(Review) (77 refs.)
  20. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 2004;5:987–995
  21. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 2000;408:979–982(see comment)
  22. Karulin AY, Hesse MD, Tary-Lehmann M, Lehmann PV. Single-cytokine-producing CD4 memory cells predominate in type 1 and type 2 immunity. J. Immunol. 2000;164:1862–1872
  23. Mason D. T-cell-mediated control of autoimmunity. Arthritis Res. 2001;3:133–135
  24. Meierhoff G, Ott PA, Lehmann PV, Schloot NC. Cytokine detection by ELISPOT: relevance for immunological studies in type 1 diabetes. Diab./Metab. Res. Rev. 2002;18:367–380(Review) (80 refs.)
  25. Miscia S, Ciccocioppo F, Lanuti P, Velluto L, Bascelli A, Pierdomenico L, et al. Abeta(1–42) stimulated T cells express P-PKC-delta and P-PKC-zeta in Alzheimer disease. Neurobiol. Aging. 2007;
  26. Monsonego A, Zota V, Karni A, Krieger JI, Bar-Or A, Bitan G, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 2003;112:415–422(see comment)
  27. Moore KW, de Waal MR, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol. 2001;19:683–765(Review) (661 refs.)
  28. Muzio M, Bosisio D, Polentarutti N, D’amico G, Stoppacciaro A, Mancinelli R, et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 2000;164:5998–6004
  29. O’Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat. Med. 2004;10:801–805(Review) (65 refs.)
  30. Ott PA, Herzog BA, Quast S, Hofstetter HH, Boehm BO, Tary-Lehmann M, et al. Islet-cell antigen-reactive T cells show different expansion rates and Th1/Th2 differentiation in type 1 diabetic patients and healthy controls. Clin. Immunol. 2005;115:102–114
  31. Ott PA, Tary-Lehmann M, Lehmann PV. The secretory IFN-gamma response of single CD4 memory cells after activation on different antigen presenting cell types. Clin. Immunol. 2007;124:267–276
  32. Palinski W, Horkko S, Miller E, Steinbrecher UP, Powell HC, Curtiss LK, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J. Clin. Invest. 1996;98:800–814
  33. Pawelec G, Hirokawa K, Fulop T. Altered T cell signalling in ageing. Mech. Ageing Dev. 2001;122:1613–1637(Review) (143 refs.)
  34. Pelfrey CM, Rudick RA, Cotleur AC, Lee JC, Tary-Lehmann M, Lehmann PV. Quantification of self-recognition in multiple sclerosis by single-cell analysis of cytokine production. J. Immunol. 2000;165:1641–1651
  35. Pifer J, Hennes JL, Lee JM, Witte PL. Age-related differences in the immune response to immunization with human Abeta42 peptide. J. Gerontol. Ser. A-Biol. Sci. Med. Sci. 2002;57:B355–B358
  36. Rentzos M, Paraskevas GP, Kapaki E, Nikolaou C, Zoga M, Rombos A, et al. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. J. Neurol. Sci. 2006;249:110–114
  37. Rosenkranz D, Weyer S, Tolosa E, Gaenslen A, Berg D, Leyhe T, et al. Higher frequency of regulatory T cells in the elderly and increased suppressive activity in neurodegeneration. J. Neuroimmunol. 2007;188:117–127
  38. Russo DM, Kozlova N, Lakey DL, Kernodle D. Naive human T cells develop into Th1 effectors after stimulation with Mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins. Infect. Immun. 2000;68:6826–6832
  39. Sakata-Kaneko S, Wakatsuki Y, Matsunaga Y, Usui T, Kita T. Altered Th1/Th2 commitment in human CD4+ T cells with ageing. Clin. Exp. Immunol. 2000;120:267–273
  40. Sandmand M, Bruunsgaard H, Kemp K, Andersen-Ranberg K, Pedersen AN, Skinhoj P, et al. Is ageing associated with a shift in the balance between Type 1 and Type 2 cytokines in humans?. Clin. Exp. Immunol. 2002;127:107–114
  41. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173–177(see comment)
  42. Schindowski K, Frohlich L, Maurer K, Muller WE, Eckert A. Age-related impairment of human T lymphocytes’ activation: specific differences between CD4(+) and CD8(+) subsets. Mech. Ageing Dev. 2002;123:375–390
  43. Shearer GM, Clerici M. Cytokine profiles in HIV type 1 disease and protection. AIDS Res. Human Retroviruses. 1998;14(Suppl 2):S149–S152(Review) (41 refs.)
  44. Trieb K, Ransmayr G, Sgonc R, Lassmann H, Grubeck-Loebenstein B. APP peptides stimulate lymphocyte proliferation in normals, but not in patients with Alzheimer's disease. Neurobiol. Aging. 1996;17:541–547
  45. Udan ML, Ajit D, Crouse NR, Nichols MR. Toll-like receptors 2 and 4 mediate Abeta(1–42) activation of the innate immune response in a human monocytic cell line. J. Neurochem. 2008;104:524–533
  46. Weksler ME, Goodhardt M. Do age-associated changes in ‘physiologic’ autoantibodies contribute to infection, atherosclerosis, and Alzheimer's disease?. Exp. Gerontol. 2002;37:971–979(Review) (48 refs.)
  47. Weksler ME, Relkin N, Turkenich R, LaRusse S, Zhou L, Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 2002;37:943–948
  48. Yang Z, Chen M, Wu R, Fialkow LB, Bromberg JS, McDuffie M, et al. Suppression of autoimmune diabetes by viral IL-10 gene transfer. J. Immunol. 2002;168:6479–6485
  49. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J. Immunol. 1999;162:3942–3949

PII: S0197-4580(08)00333-3

doi: 10.1016/j.neurobiolaging.2008.09.007

Neurobiology of Aging
Volume 31, Issue 10 , Pages 1732-1742 , October 2010

Article Tools

* Image Usage & Resolution